Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
Latest Information Update: 19 Mar 2024
At a glance
- Drugs Apalutamide (Primary) ; LHRH receptor agonists (Primary) ; Strontium-89 (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 14 Mar 2024 Status changed from not yet recruiting to recruiting.
- 27 Feb 2023 New trial record